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Abstract
Gastrointestinal (GI) cancers are one of the most common malignancies 
worldwide, with high rates of morbidity and mortality. Myeloid-derived 
suppressor cells (MDSCs) are major components of the tumor microenvironment 
(TME). MDSCs facilitate the transformation of premalignant cells and play roles 
in tumor growth and metastasis. Moreover, in patients with GI malignancies, 
MDSCs can lead to the suppression of T cells and natural killer cells. Accordingly, 
a better understanding of the role and mechanism of action of MDSCs in the TME 
will aid in the development of novel immune-targeted therapies.
Key Words: Myeloid-derived suppressor cells; Gastrointestinal cancers; Immune 
checkpoint inhibitors; Tumor progression
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: In patients with cancer, the levels of myeloid-derived suppressor cells 
(MDSCs) are presumed to be of prognostic and predictive value. Recent studies have 
shown that MDSCs appear to be independent prognostic factors in gastrointestinal 
cancer. In addition, therapeutics that target MDSCs have been shown to enhance anti-
tumor immune responses in animal models. Consequently, a better understanding of 
the role and mechanism of action of MDSCs in the tumor microenvironment may aid 
in the development of novel immune-targeted therapies.
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In 2018, 4.8 million new diagnoses of gastrointestinal (GI) cancer and 3.4 million 
related deaths were reported globally. The incidence of GI cancer is 26% worldwide, 
accounting for 35% of all cancer-associated mortalities[1]. Numerous stromal and 
immune cells and soluble markers are related to the immunosuppressive network in 
the tumor microenvironment (TME)[2]. This network is involved in tumor cell growth 
and the blockade of anti-tumor immune responses, which subsequently promote the 
progression and invasion of tumor cells[3]. Macrophages, monocytes, and dendritic 
cells (DCs) represent a subgroup of leukocytes called myeloid cells, which are 
generated from polymorphonuclear granulocytes[4]. Myeloid-derived suppressor cells 
(MDSCs) are a heterogeneous population of immature myeloid cells that arise from 
myeloid progenitor cells[5]. They play a key role in tumor-associated immune evasion, 
angiogenesis, and tumor metastasis[6,7].
In patients with cancer, the levels of MDSCs are thought to have prognostic and 
predictive significance[3]. Recent studies have examined the role of MDSCs in solid 
tumors, and discovered that they appear to be independent prognostic factors in GI 
cancer[8,9]. In a meta-analysis of 17 studies with 1115 patients with GI malignancies, 
patients with a higher number of MDSCs at tumor sites and peripheral blood had 
higher mortality rates (hazard ratio: 3.35, 95% confidence interval: 1.46-7.68; P = 
0.0004), risk of relapse, and tumor progression. The authors concluded that MDSC 
levels have prognostic and predictive value in cancer patients[10]. Additionally, higher 
levels of MDSCs in patients with cancer are associated with advanced tumor stage and 
a poor clinical prognosis[11]. Shibata et al[12] evaluated 123 patients with advanced GI 
malignancy, including 62 with colorectal cancer (CRC), 43 with gastric cancer (GC), 
and 18 with esophageal malignancies, and found that overall survival (OS) was 
significantly shorter in stage IV GI cancer patients with high MDSC levels than in 
those with low MDSC levels (P < 0.05). Because MDSCs have a significant role in 
modulating cancer progression and metastasis by inhibiting the anti-tumor reactivity 
of T cells and natural killer (NK) cells, targeting MDSCs with immune checkpoint 
inhibitors (ICIs) can alleviate their pro-tumorigenic functions. Therefore, in this 
systematic review, we summarize the characteristics and proposed function of MDSCs 
in the TME and their relationship to prognosis in patients with GI cancers.
MATERIALS AND METHODS
PubMed/MEDLINE databases were explored with search strategies using search 
keywords “MDSCs,” “gastrointestinal cancers,” “prognosis,” “tumor progression,” 
and “mortality rate,” to categorize studies published between 2006 and 2020. A total of 
128 articles were reviewed by the authors for relevance to MDSCs and GI cancers, 
including retrospective, cross-sectional, case reports, and cohort studies, of which 85 
papers were selected that met our selection criteria.
MDSC MECHANISM OF ACTION
MDSCs are myeloid-derived heterogeneous cells with potent immune regulatory 
functions. They are derived from the myeloid lineage of immune cells that give rise to 
macrophages, granulocytes, and immature DCs[13]. Monocytic MDSCs (M-MDSCs) and 
polymorphonuclear MDSCs (PMN-MDSCs) are the two major myeloid subsets of 
MDSCs[14]. Phenotypically and morphologically, they are equivalent to monocytes and 
neutrophils, respectively (Table 1)[15].
The process of myelopoiesis is driven by granulocyte-macrophage colony-
stimulating factor (GM-CSF) in normal physiological conditions. Ultimately, GM-CSF 
and M-CSF induce the differentiation of granulocytes and macrophages from a 
common myeloid precursor that transforms into a common myeloblast[16]. Myeloid 
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Table 1 Two main categories of myeloid-derived suppressor cells and their immunosuppressive functions[59]
Type of 
MDSC Markers in humans Immunosuppression mediator Mechanism of immunosuppression
PMN-MDSCs CD11b+CD14−CD15+HLADR− or 
CD11b+CD14−CD66b+ or LOX-1+
ARG1, ROS Suppressing immune responses mainly in an antigen-
specific manner; ROS production
M-MDSCs CD11b+CD14+CD15−HLADRlow/− NO, ARG1, and cytokines such as 
TGF-β and IL-10
Suppressing T cell responses, both in antigen-specific and 
non-specific manners; production of NO and cytokines
ARG1: Arginase 1; IL-10: Interleukin-10; M-MDSCs: Monocytic myeloid-derived suppressor cells; NO: Nitric oxide; PMN-MDSCs: Polymorphonuclear 
myeloid-derived suppressor cells; ROS: Reactive oxygen species; TGF-β: Transforming growth factor-beta; MDSC: Myeloid-derived suppressor cell.
DCs eventually arise from monocytic as opposed to granulocytic lineages[17]. However, 
the hypersecretion of these mediator factors during chronic inflammation and cancer 
leads to the generation of MDSCs[18]. For example, inflammatory cytokines such as 
interleukin 6 (IL-6), IL-1β, and IL-3 and C-X-C chemokine receptor type 4 (CXCR4) and 
CXCL12 can lead to the induction and proliferation of MDSCs in peripheral blood and 
tumor sites in cancer patients[7,19]. The most important function of MDSCs is 
immunosuppression, mainly of target T cells (Figure 1)[14].
Several in vitro and in vivo studies have documented the mechanisms underlying the 
immunosuppressive actions of MDSCs. Arginase 1 (ARG1), inducible nitric oxide 
(iNOS), reactive oxygen species, and reactive nitrogen species are important 
suppressive factors produced by MDSCs[20,21]. Cao et al[22] reported that PMN-MDSCs 
store ARG1 and secrete it to the TME. ARG1 and NOS activities lead to cellular 
depletion of L-arginine (referred to as L-arg), which is an essential substrate for T cell 
proliferation[22,23]. Similar to T cells, depletion of L-arg also impairs the function of NK 
cells[24].
In addition to immunosuppressive factors, MDSCs can overpower T cell functions 
by directly engaging with T cell inhibitory and apoptotic receptors. Activated MDSCs 
express high levels of Fas ligand (referred to as Fas L), programmed death-ligand 1 
(PD-L1), and galectin-9. Subsequently, the interaction between these ligands with their 
receptors on T cells leads to T cell exhaustion via PD-L1/programmed cell death 
protein 1 (PD-1) or T cell apoptosis through the Fas L/Fas and galectin-9/T cell 
immunoglobulin and mucin domain-3 pathways[25]. Generally, M-MDSCs have more 
suppressive effects than PMN-MDSCs[26]. Moreover, MDSCs can stimulate and recruit 
regulatory T cells (Tregs) to the TME[27]. Tregs suppress anti-tumor immunity, and the 
interaction between MDSCs and Tregs create a strong blockade preventing cytotoxic 
immune cells from mounting an anti-tumor attack[28]. Elevated levels of Tregs are 
associated with poor survival in patients with hepatocellular carcinoma (HCC) and 
pancreatic cancer[29,30]. Regarding metastasis, MDSCs can promote angiogenesis by 
secreting IL-28 [interferon lambda (IFN-λ)] and matrix metalloproteinase (MMP)-9, 
promoting the invasion and migration of tumor cells[31].
MARKERS OF MDSCS IN PERIPHERAL BLOOD
MDSCs are categorized according to their phenotype, which includes several 
recognized surface markers, such as cluster of differentiation 33 (CD33), CD11b, or 
human leukocyte antigen-DR isotype (HLA-DR), as well as by the lack of expression of 
markers distinctive of mature lymphoid cells, such as CD3, CD19, and CD56[32]. 
Typically, flow cytometry is performed to isolate MDSCs from peripheral 
mononuclear blood cells (PBMCs)[33]. Fluorescent-labeled monoclonal antibodies are 
used to distinguish M-MDSCs and granulocytic MDSCs (G-MDSCs). M-MDSCs are 
identified as CD11b+CD14+CD33highHLA-DR-/low and CD66b, whereas G-MDSCs are 
recognized as CD11b+CD14-CD33lowHLA-DR-CD66b+[34]. MDSCs can be distinguished 
from other immune suppressor cells within the myeloid lineage, e.g., tumor-associated 
macrophages and macrophage type 2, by other specific surface markers, including 
CD163 and F4/80[35].
Farshidpour M et al. MDSC in gastrointestinal cancers
WJGO https://www.wjgnet.com 4 January 15, 2021 Volume 13 Issue 1
Figure 1 Chronic inflammation activates myeloid-derived suppressor cell generation, migration, and immunosuppression in the tumor 
microenvironment. Several cytokines and stimulator factors secreted by stroma and tumor cells (e.g., VEGF, granulocyte-macrophage colony-stimulating factor, 
IL-1, IL-6, HIF-1α, TGF-β, COX-2) trigger myeloid-derived suppressor cell (MDSC) generation and migration. Cytokines (e.g., CCL2, CCL3, CCL4, CCL5, CXCL1) 
stimulate the migration of MDSCs into the tumor microenvironment. At the tumor site, MDSCs undergo activation (via TNF, IL-10, IL-1, IL-6, IFN-γ, COX-2, HIF-1α, 
etc.) and suppress the anti-tumor reactivity of T and natural killer cells. Cross-talk between MDSCs and dendritic cells (DCs) impairs DC function and promotes tumor 
progression[81]. GM-CSF: Granulocyte-macrophage colony-stimulating factor; PMN-MDSC: Polymorphonuclear myeloid-derived suppressor cells; M-MDSC: 
Monocytic myeloid-derived suppressor cells; MDSC: Myeloid-derived suppressor cell; DC: Dendritic cell; ARG-1: Arginase 1; NOS: Nitric oxide; PD-L1: Programmed 
death-ligand 1; NK: Natural killer; ROS: Reactive oxygen species.
MDSCS IN GI MALIGNANCIES
Esophageal cancer
High levels of circulating MDSCs in esophageal cancer are associated with a poor 
prognosis[5]. Elevated MDSCs in the blood are correlated with elevated numbers of 
immunosuppressive cells, including Tregs[5]. Jiao et al[36] evaluated 31 esophageal 
cancer patients and 26 healthy controls (HCs), and found that MDSC numbers in the 
peripheral blood were increased 15-fold in esophageal cancer patients compared to 
HCs. The authors also showed that the plasma levels of ARG1 were 3-fold higher in 
cancer patients than in HCs. Xu et al[37] showed that 178 patients with esophageal 
cancer had a high level of G-MDSCs (> 82.5%), which were correlated with high 
morbidity due to the development of sepsis postoperatively after esophageal cancer 
surgery. The authors suggested that the level of G-MDSCs may be used to determine 
the incidence of sepsis in preoperative esophageal cancer patients postoperatively, and 
could improve the mortality of cancer-associated sepsis by targeting the level of 
MDSCs.
Additionally, a study by Chen et al[38] found that the levels of IL-6 and MDSCs 
predicted the prognosis and treatment response in mice with esophageal squamous 
cell carcinoma (SCC). The levels of MDSCs induced by IL-6 were linked to tumor 
growth and a poor prognosis. The authors concluded that targeted therapy against IL-
6 with rapamycin or casein kinase 2 inhibitors might be a potential treatment modality 
for esophageal SCC[38,39].
GC
According to the Global Cancer Observatory (GLOBOCAN) 2018 database, GC is the 
fifth most common cancer and third most deadly cancer worldwide, with an estimated 
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783000 deaths in 2018[40]. Li et al[41] documented the levels of MDSCs in the peripheral 
blood of 21 GC patients who had not previously received treatment, and noted that the 
levels of MDSCs in these patients were about 4-fold higher than in the control groups. 
The authors concluded that cancer cell differentiation and lymph node metastasis are 
mostly related to the presence of M-MDSCs. They also showed that treatment with 
epirubicin and paclitaxel regimens can reduce the level of MDSCs in these patients, 
potentially leading to better outcomes for patients due to inhibition of cancer 
progression. Moreover, in 29 patients with GC and 18 HCs, MDSCs were increased in 
stage IV patients compared with HCs, and the 2-year survival rate of patients with 
higher levels of MDSCs was significantly poorer (median OS: 498 d vs 473 d; P = 
0.048), but no significant difference was observed in survival among patients with 
stage I, II, and III GC[42]. Previously, we reported that schlafen (SLFN) 4-expressing 
myeloid cells recruited to the stomach during Helicobacter infection undergo a 
phenotypic shift to G-MDSCs under the influence of damage-associated molecular 
pattern (DAMP) signaling and the production of IFN-α[43,44]. SLFN4 is a myeloid cell 
differentiation factor that controls myelopoiesis[45]. These SLFN-expressing MDSCs 
secrete factors including microRNAs, which can be detected in the peripheral blood as 
a biomarker and promote epithelial cell growth. This sustained immune dysregulation 
creates a microenvironment capable of supporting GC development[46].
HCC
HCC is a leading cause of death in cirrhotic patients. Per the GLOBOCAN 2018 
database, 841000 new cases of primary liver cancer and 782000 deaths due to HCC 
occurred that year[40]. In a prospective case-control study, Elwan et al[47] demonstrated a 
higher number of MDSCs in the peripheral blood of cirrhotic groups without HCC 
than in patients with cirrhosis and HCC compared to patients in control groups. They 
showed that mean MDSC counts in the peripheral blood of cirrhotics without HCC 
group and cirrhotics with HCC group were about 3.5-fold and 5-fold higher compared 
to the control groups, respectively. Although not statistically significant, the authors 
reported a low number of MDSCs in the ascitic fluid of patients with both cirrhosis 
and HCC. Additionally, they investigated the correlation of levels of IFN-γ and alpha-
fetoprotein with MDSC level. Their data showed that alpha-fetoprotein was positively 
and INF-γ was negatively correlated with MDSC count in the HCC group[47]. A high 
frequency of MDSCs in the PBMCs of patients with HCC has been linked to more 
aggressive forms of HCC and poor clinical outcomes following local ablation, 
hepatectomy, or hepatic arterial infusion chemotherapy[48,49]. A cohort study by Bayik 
et al[50] showed an upsurge in circulating MDSC frequency in 114 patients with a 
secondary liver cancer, including CRC with liver metastases and neuroendocrine 
tumors, compared to individuals with benign lesions.
Data from animal models have shown that myeloid cells secrete MMPs, serine 
proteases, and cysteine cathepsins, which facilitate tumor cell invasion and metastasis 
by disrupting cell adhesions[51]. Tumor angiogenesis in HCC can be promoted by 
MDSCs by producing high levels of MMP-9 in HCC[52].
Pancreatic cancer
The incidence of pancreatic ductal adenocarcinoma has significantly increased 
worldwide over the last 30 years, with a 5-year survival time less than 8%[53]. Khaled 
et al[54] demonstrated that G-MDSCs, but not M-MDSCs, are much higher in circulation 
and in the tumor tissue of patients with pancreatic cancer compared to HCs or those 
with chronic pancreatitis. These results suggest that the high level of G-MDSCs in 
pancreatic cancer plays a key factor in tumor development and progression. A cohort 
study reported that the percentages of all subpopulations of MDSCs were higher in 
patients with intraductal papillary mucinous neoplasm (IPMN) than in HCs, and were 
even higher in those with pancreatic adenocarcinoma. Although there was a trend 
towards higher MDSC levels in pancreatic cancer vs IPMN, it was not statistically 
significant (P = 0.33)[55].
CRC
A recent study reported that CRC cells induce an increase in the number of MDSCs by 
producing inflammatory factors, such as transforming growth factor-beta, IL-10, and 
ARG1[56,57]. Consequently, T cell proliferation can be suppressed by tumor-derived 
MDSCs and promote tumor cell growth via oxidative metabolism. Previously, it was 
shown that the numbers of circulating Tregs and MDSCs are significantly reduced 
following tumor resection in patients with CRC. These data indicate that 
immunosuppression can be mitigated by reducing the number of MDSCs and Tregs in 
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patients with CRC after reducing the tumor burden[57]. Tada et al[58] showed that 
patients with unresectable metastatic CRC with high M-MDSC, low CD4+, or low 
CD8+ effector memory T cell levels had significantly shorter progression-free survival.
MDSC-TARGETED THERAPY
Many studies have examined MDSCs as the core of targeted therapeutic strategies to 
improve tumor control in experimental animal models. These targeted therapies could 
be achieved by reducing MDSC numbers, hindering their trafficking and migration, or 
inhibiting their immunosuppressive function (Table 2)[59].
Because of variances in immunophenotype and mechanisms of suppression in the 
TME and diverse nature of human MDSCs, it is challenging to target human 
MDSCs[60]. Wang et al[61] treated pancreatic cancer patients with cytokine-induced killer 
(CIK) cell immunotherapy, CIK plus gemcitabine, and 5-fluorouracil (5-FU), and 
analyzed the levels of MDSCs in the peripheral blood pre- and post-treatment. The OS 
of metastatic pancreatic patients was increased with the combination of CIK and 
chemotherapy (gemcitabine and 5-FU) compared to patients treated with only CIK. 
Also, Jiang et al[62] reported that the quality of life and 2-year survival rate improved in 
patients with advanced GC following combining chemotherapy (5-FU and oxaliplatin) 
with CIK cell treatment compared to treatment with chemotherapy alone. Tadalafil, 
the Federal Drug Administration-approved phosphodiesterase-5 inhibitor, can 
suppress MDSCs through downregulation of ARG1 and iNOS activities in several 
preclinical models[63-65]. Rawat et al[66] showed in aflatoxin-induced HCC rats, that 
tadalafil reduced the level of glutamic oxaloacetic transaminase, an important enzyme 
that facilitates carbohydrate and protein metabolism in cancer cells. A previous study 
showed that treatment with tyrosine kinase inhibitors, such as sunitinib, reduced the 
number of MDSCs and Tregs in animals with intrahepatic colorectal metastases[67]. The 
authors also showed that the number of MDSCs was significantly reduced from 53.9% 
in phosphate-buffered saline-treated mice to 39% in sunitinib-treated mice. Sunitinib 
has established efficacy against advanced GI stromal tumors[68].
Treatment of esophageal SCC with 1α,25-dihydroxyvitamin D3 (calcitriol) has been 
shown to inhibit MDSC proliferation induced by IL-6 stimulation in C57 mice. 
Therefore, it has been proposed that this treatment may be a promising strategy for the 
prevention and treatment of esophageal SCC[69].
ICIs such as cytotoxic T-lymphocyte-associated protein 4 (ipilimumab and 
tremelimumab), PD-1 (pembrolizumab and nivolumab), and PD-L1 (atezolizumab, 
avelumab, and durvalumab) are promising treatment strategies that can be applied 
across numerous solid tumors[70]. Pembrolizumab is a therapeutic antibody that blocks 
PD-1, and has shown promising anti-tumor activity in advanced GC[71]. Although ICIs 
show great therapeutic benefits, substantial GI side effects such as colitis and GI 
bleeding can limit their use[72]. However, due to immunosuppression, which is 
regulated by MDSCs, some patients with cancer may develop resistance to ICIs[73]. 
Therefore, it is important to inhibit MDSC proliferation and migration to the TME by 
different strategies, such as anti-CXCR2 monoclonal antibody, to enhance PD-1 
efficacy[74].
CORONAVIRUS-19 AND MDSCS
In this age of coronavirus-19 (COVID-19), we would be remiss not to address what is 
currently known about activation of the host’s immune response, in particular MDSCs, 
by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Plasmacytoid DCs 
(pDCs) are the major source of tissue-derived type 1 IFNs in response to tissue 
antigens and activation of DAMPs. Typically, intracellular Toll-like receptors (TLRs) 
found on endosomes that mediate this pathway evolve to defend the cell against viral 
pathogens[75]. Thus, we queried whether coronavirus infections might be modulated by 
pDCs residing in the GI tract. Apparently, SARS-CoV-2 induces a massive anti-viral 
response by secretion of IFN-α from pDCs via TLR7[76]. The severity of COVID-19 
infection might correlate with the activation of endosomal TLRs on pDCs in the GI 
tract and increased myeloid cell polarization to MDSCs. If this occurs, the cellular 
immune response to the virus could be rendered ineffective, suggesting that those 
with severe disease exhibit higher levels of MDSCs than those with mild disease. 
Indeed, the limited studies available of COVID-19 patients have shown that the MDSC 
population expands in those with severe disease[77,78]. Although T cell exhaustion from 
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Table 2 Potential therapeutic strategy for targeting myeloid-derived suppressor cells
Strategy Agents
Blocking TDFs from being produced or from reaching the bone marrow
Key cytokines, such as IL-6 or S100A8/A9, could be directly targeted[82,84]
Targeting the IL-6 receptor (tocilizumab)[83]
Inhibiting generation of MDSCs from bone marrow progenitors or inducing apoptosis of 
circulating MDSCs[6]
Gemcitabine, 5-fluorouracil, sunitinib, and zolendronate[84]
Preventing trafficking of myeloid cells from the marrow to peripheral lymphoid organs or to 
the tumor microenvironment[6]
Drugs targeting chemokines CXCR2, CXCR4, and 
CSF1R[14]
Directly blocking MDSC suppression of T cells[85] Phosphodiesterase type 5 inhibitors, e.g., sildenafil and 
tadalafil, or cyclooxygenase 2 inhibitors[63]
Drugs that would promote differentiation of MDSCs into proficient antigen-presenting cells 
that can stimulate tumor-specific T cells and/or into mature leukocytes[85]
All-trans retinoic acid, vitamin D3, and the DNA-
methylating agent 5-azacytidine[85]
MDSCs: Myeloid-derived suppressor cells; CSF1R: Colony-stimulating factor 1 receptor; CXCR2: C-X-C motif receptor 2; CXCR4: C-X-C motif receptor 4; 
IL-6: Interleukin-6; TDFs: Tumor-derived factors.
the cytokine storm that COVID-19 patients display is the leading cause for severe 
disease, massive production of immune suppressor cells also explains the 
lymphopenia occurring in many of these patients[79,80]. A better understanding of what 
controls MDSCs will facilitate not only therapeutic treatments but may ultimately help 
to predict who will respond to vaccination. Whether patients who recover from these 
infections are predisposed to chronic disorders, such as autoimmune diseases and 
cancer, will require long-term follow up of these patients over decades.
CONCLUSION
This review article provides a better understanding of the role and mechanism of 
action of MDSCs in GI malignancies. MDSCs are one of the most important elements 
in the TME. In patients with GI cancer, MDSCs can lead to immunosuppression, and 
they play an important role in premalignant cell transformation, tumor growth, and 
metastasis. A higher number of MDSCs at tumor sites and peripheral blood is 
correlated with higher mortality rates, risk of relapse, and tumor progression. 
Therefore, monitoring circulating MDSC levels might have prognostic and predictive 
value in patients with GI malignancies. The benefit of targeting treatment against 
MDSCs as a combination therapy has been shown. Consequently, a better 
comprehension of the role and mechanism of action of MDSCs in the TME may aid in 
the development of novel immune-targeted therapies. Further prospective studies are 
needed to understand the characterization and clinical value of MDSCs and more 
selective anti-MDSC therapies with improved therapeutic outcomes.
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